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Abstract 
Background: genome-wide association studies of Major Depressive Disorder (MDD) 
have identified few significant associations. Testing the aggregation of genetic 
variants in particular biological pathways may be more powerful. Regional 
heritability analysis can be used to detect genomic regions contributing to disease 
risk. 
 
Methods: we integrated pathway analysis and multi-level regional heritability 
analyses in a pipeline designed to identify MDD-associated pathways. The pipeline 
was applied to two independent GWAS studies (GS:SFHS, N=6,455) and PGC:MDD 
(N=18,755). A polygenic risk score (PRS) composed of SNPs from the pathway most 
consistently associated with MDD was created and its accuracy to predict MDD using 
AUC, logistic regression and linear mixed model (LMM) analysis was tested.  
 
Results: In GS:SFHS, four pathways were significantly associated with MDD, and 
two of these explained a significant amount of pathway-level regional heritability. In 
PGC:MDD, one pathway was significantly associated with MDD. Pathway-level 
regional heritability was significant in this pathway in one subset of PGC:MDD. For 
both samples the regional heritabilities were further localized to the gene and 
sub-region levels. The NETRIN1 signaling pathway showed the most consistent 
association with MDD across the two samples. PRSs from this pathway showed 
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competitive predictive accuracy when compared with the whole-genome PRSs when 
using AUC statistics, logistic regression and LMM. 
 
Conclusions: these post-GWAS analyses highlight the value of combining multiple 
methods on multiple GWAS data for the identification of risk pathways for MDD. 
The NETRIN1 signaling pathway is identified as a candidate pathway for MDD, and 
should be explored in further large population studies.  
 
Introduction 
Major Depressive Disorder (MDD) contributes 8.2% of the global burden of 
disease(1). Twin studies have estimated the narrow sense heritability of MDD to be 
37%, confirming the involvement of genetic factors in MDD(2). However, published 
GWAS of MDD have only detected two loci associated with recurrent MDD at 
genome-wide significance in a study of Chinese women(3,4), despite of the success of 
GWAS for other psychiatric disorders(5). Additional methods for detecting the 
aggregate effects of sub-genome-wide significant risk variants are required to better 
extract information from available data.  
 
Two lessons relevant to MDD can be learned from previous studies of polygenic 
diseases. First, disease-associated variants are enriched in functionally annotated 
regions of the genome(6). Second, the small signals from individual genetic variants 
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contrast with the stronger signals from individual pathways(7). Using GWAS 
summary statistics, a recent PGC study identified disease-specific and shared 
pathways across multiple psychiatric diseases(8). These findings suggest that the 
cumulative effects from single variants converge on biological pathways and the 
pathways themselves may be more tractable targets for GWAS. In the current study, 
we sought to test whether the aggregate effects of low-penetrance variants become 
detectable at the pathway level in MDD. 
 
Various approaches have been developed to identify the association between 
pathways and phenotype. Methods designed to be applied to raw genotypes or 
summary statistics of GWAS have been developed(9). The optimal method should 
depend on the data type available and the research goals. For instance, a 
pathway-based study demonstrated the feasibility of identifying pathways and genes 
associated with schizophrenia using analytical methods that are designed for different 
data types (raw genotypes and GWAS summary statistics) in three independent 
samples (10).  
 
Genomic Restricted Maximum Likelihood (GREML) analysis methods (11) can be 
used to estimate the additive variance contributed from all the genotyped SNPs using 
linear mixed modeling (LMM). They may also be adapted to further partition the 
variance components by functionally annotated SNP categories (11-13). Generally, for 
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polygenic traits the proportion of the phenotypic variance explained by the SNPs was 
proportional to the number of SNPs involved(14). However, genomic regions that 
explain more heritability than expected when accounting for the number of SNPs they 
contain have been uncovered. These regions usually overlap with regulatory, genic or 
conserved regions of the human genome(12,13,15,16). The locally enriched 
heritability is defined as regional heritability. Regional heritability analysis can be 
applied to identify genomic regions that contribute a significant proportion of 
heritability as an alternative association test(17). Using this method, a recent study 
identified more genomic regions reaching the suggestive level of significance than 
GWAS, suggesting that it is capable of capturing some of the signals not detected by 
a single SNP association test(18). 
 
In this study, we sought to identify biological pathways associated with MDD by 
making use of well-annotated molecular pathway databases and two independent 
samples of European ancestry. Each sample was run through a pipeline in which a 
non-hypothesis-driven pathway analysis was applied to identify MDD-associated 
pathways and that was followed by multi-level regional heritability analyses to 
quantify and narrow down the genetic contribution from the candidate pathways. 
Using this pipeline, we observed overlaps in the identified MDD-candidate pathways, 
genes and sub-regions between samples. Finally, in order to test for the predictive 
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value of the pathway most consistently associated with MDD across samples, we 
compared the predictive accuracy of pathway-derived MDD PRS to 
whole-genome-derived PRS.  
 
Methods and Materials 
The Tayside Research Ethics Committee(reference 05/S1401/89) provided ethical 
approval for the study. 
 
Datasets  
Generation Scotland: The Scottish Family Health Study (GS:SFHS)  
GS:SFHS included 21,387 subjects(Nmale=8,772, Nfemale=12,615; Agemean=47.2). 
Participants were recruited from the registers of collaborating general practices via 
their Community Health Index(19). A structured clinical interview was used for the 
diagnosis of MDD DSM-IV mood disorders (SCID)(20)(see Supplement). By the time 
we performed this study, 9,863 individuals were genotyped using the Illumina Human 
OmniExpressExome -8- v1.0 array(21). Details of genotyping are described in detail 
elsewhere(22). Quality control(QC) and imputation method are described in the 
Supplement. In total, 592,690 genotyped and 2,163,848 imputed autosomal SNPs 
passed QC criteria and were used in subsequent analyses. Since close relatives can bias 
the pathway analysis and SNP heritability estimation, the function ‘--grm-cutoff 0.025’ 
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in GCTA was used to remove one of each pair of individuals with estimated 
relatedness larger than 0.025 while maximizing the remaining sample size(11), 6,455 
subjects (1,123 MDD cases and 5,332 controls) remained in the analyses described 
below.  
 
PGC Major Depression Dataset (PGC:MDD) 
The Psychiatric Genomics Consortium provided summary statistics from the GWAS 
mega-analysis of MDD from the discovery phase and individual genotypes from the 
nine primary cohorts in this dataset. These data included 18,759 subjects of European 
ancestry (NMDD_case=9,240, Ncontrol=9,519)(4). Cases were required to have a diagnosis 
of DSM-IV lifetime MDD (see Supplement). Summary statistics included GWAS P 
values and odds ratio information for 1,235,110 SNPs post-imputation(HapMap3). 
We carried out additional QC of these summary statistics using the following 
inclusion thresholds: info score≥ 0.8, and MAF≥0.01, after which 1,074,100 SNPs 
remained and were used in pathway analysis and polygenic risk profiling.  
 
Imputed genotype data from nine PGC:MDD cohorts were provided by PGC for the 
regional heritability analysis. Best-guess imputed genotypes from each cohort were 
accepted at the same level of QC as GS:SFHS. After removing one of each pair of 
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close relatives(t>=0.025), the remaining 17,845 subjects were used in the downstream 
analyses(see Table s1 for sample information).  
 
A pipeline for identification of pathways associated with MDD. 
This pipeline includes two stages of analyses: (1) a pathway analysis to identify 
MDD-associated pathways, and (2) multi-level (pathway/gene/sub-region) regional 
heritability analyses to narrow down the signals of the association. The multi-level 
regional heritability analyses for pathways identified by stage 1 were tested on the 
same sample in which they were first identified, and the test statistics from stage 2 are 
therefore potentially biased towards finding a more significant association. However, 
by applying the pipeline to two or more samples and by seeking replication across 
these the pipeline could provide independent replication of findings (as shown in 
current study). Further details of the pipeline are shown in Figure 1 and Table s2. 
Stage1: Pathway analysis  
For both samples, SNPs were annotated to 1,035 pathways(640 from Reactome, 216 
from Biocarta and 179 from KEGG)(Supplement). For the GS:SFHS genotype dataset 
(NSNP=592,690; Nsample=6,455), the “gene set ridge regression in association studies” 
algorithm (GRASS)(23) was used to identify pathway-MDD associations using only 
the genotyped SNPs(Supplement). False Discovery Rate (FDR)-adjusted P values 
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(NFDR=1035) were calculated using the function p.adjust in the R package 
‘stats’(24,25). For the PGC:MDD GWAS summary results dataset(NSNP=1,074,100), 
Meta-Analysis Gene-set Enrichment of variaNT Associations(MAGENTA)(26) was 
used to test for the enrichment of genetic associations in each pathway for MDD, as 
just summary statistics were available for this part of the study 
(http://www.med.unc.edu/pgc/downloads) and MAGENTA was designed to exploit 
summary data from GWAS results(Supplement). MAGENTA reports a nominal P 
value and an estimated FDR per pathway(NFDR=1035). 
 
Stage2: Estimation of MDD phenotypic variance explained by imputed genotypes of 
regional SNPs (regional heritability) 
Imputed SNPs were used in this analysis to avoid underestimating the regional 
heritability(12). For PGC:MDD, due to the heterogeneity caused by factors such as 
different ancestry and clinical diagnosis across samples(4)(Table s1), as well as 
analyzing the regional heritability in the combined dataset, we performed the 
SNP-heritability analysis in the three subsets used by the PGC:MDD consortium to 
group the nine cohorts (27)(Table s1).  
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We applied GREML using linear mixed modeling(LMM)(11) to estimate the variance 
explained by SNPs from genic regions of genes from candidate pathways and the 
sub-regions of candidate genes. A Log likelihood ratio test (LRT) was applied to test 
the significance of the estimated variance component(Supplement). Permutation 
analysis was performed to test whether the pathway-level regional heritability in 
candidate pathways was significantly greater than that expected by 
chance(Supplement). These analyses were performed in GCTA(11). To map regional 
heritability at sub-region level, regional heritability mapping(RHM, a modified 
GREML analysis) was applied using a sliding window to scan across the genic region 
of candidate genes(Supplement).  
 
Polygenic profiling 
Polygenic risk scores (PRS)(28) estimate the genetic risk of MDD for unrelated 
individuals(Nsample=6,455) in GS:SFHS by adding the number of risk alleles an 
individual had, weighted by the effect size estimated in PGC:MDD(4)(Supplement).  
  
To compare PRS derived from the pathway SNPs to that derived from the 
whole-genome SNPs, logistic regression and linear mixed models (LMM) were used 
to estimate the phenotypic variance explained by PRSs. (1)Logistic regression: PRS 
was treated as a fixed effect and MDD phenotype was regressed on PRS (other 
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covariates: age, age
2
, sex, top 4 principal components). The variance explained by 
PRS was calculated as Nagelkerke's R
2
 on the observed scale(29). Permutation 
analysis was conducted to set an empirical threshold by creating PRS from 1000 
circularly permuted SNP sets(30)which were then fitted in logistic regression. 
(2)LMM: we developed a PRS-bin-relationship-matrix method where the MDD 
phenotype variation was explained by the PRS similarity between subjects in the 
framework of LMM. The PRS similarity reflects relatedness in terms of the 
MDD-genetic risk and the variance explained by the PRS-similarity as a random 
effect was estimated using REML and tested using LRT(Supplement). 
 
Finally, the area under the receiver-operating characteristic curve(AUC) was 
calculated to determine the efficacy of PRSs in correctly classifying MDD cases and 
controls using equation 2 in (31). 
 
Results 
 
To identify candidate pathways for MDD, a pipeline that combines pathway and 
multi-level(pathway/gene/sub-region) regional heritability analyses was applied to 
two independent samples, GS:SFHS and PGC:MDD, respectively. Detailed 
information of the analytical pipeline and the data usage is shown in Figure 1 and 
Table s2.  
Yanni Zeng 
 12 
 
Identification of MDD-associated pathways in GS:SFHS 
Pathway analysis: applying GRASS in GS:SFHS, four pathways were significantly 
associated with MDD after FDR correction(NFDR=1035). These comprised the 
following: three pathways from REACTOME (MTORC1 mediated signaling, 
NETRIN1 signaling, ABCA transporters in lipid homeostasis) and one pathway from 
BIOCARTA (FEEDER pathway) (Table 1).  
 
Regional heritability analysis: using GREML, the estimate of   
  the heritability 
explained by all GWAS SNPs) for MDD was 0.25 (se=0.10) in GS:SFHS(Table s4A). 
To further investigate the regional heritability captured by SNPs from pathways that 
were significant in pathway analysis, for each pathway, we partitioned the 
genome-wide SNPs into two sets: (1) SNPs from the pathway and (2) the remaining 
SNPs. We then jointly estimated their contribution to MDD phenotypic variance in 
LMM. Among the four pathways that were significant in pathway analysis, two 
yielded significant P values(post-FDR-adjustment, NFDR=4) based on the LRT for 
pathway-level regional heritability in MDD, with the highest regional heritability 
estimated in the NETRIN1 signaling pathway(   
  =0.014, se=0.009, 
Plrt_FDR=0.019)(Table 2). Permutation test across the circularly permuted SNP-sets 
with the same set size for the two pathways showed that the detected 
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pathway-regional-heritability was not attributable to gene set size and LD structures 
(NETRIN1 signaling: Pperm =0.018; MTORC1 mediated signaling pathway: 
Pperm=0.01)(Supplement).  
 
To narrow down the signals from the two pathways where significant pathway-level 
regional heritability was detected, gene-level regional heritability was estimated for 
single genes in the two pathways. The heritabilities for three genes (DCC, UNC5D 
and SIAH2) from the NETRIN1 pathway and one gene (RPTOR) from MTORC1 
mediated signaling pathway obtained nominal significance in LRT(Table s5A). 
Among them, the receptor proteins encoded by DCC and UNC5D share the same 
ligand, Netrin-1, a key molecular signal in the NETRIN signaling pathway(32). To 
fine map the regional heritability within the two receptor genes and further explore if 
any of the sub-regions that conferred heritability overlapped with any functional 
domains, RHM was applied to the 2 genes using a fixed sliding window to scan 
across their genic regions(Figure 2,s1). Block 6 in DCC and Block 1 in UNC5D yield 
significance in LRT (Block6DCC: Plrt_bonf=0.021; Block1UNC5D:Plrt_bonf=0.028)(Table 
s6A). Block 6 in DCC overlapped with the fourth Immunoglobulin-like domain 
(Ig)(Figure 2)(33). Block 1 in UNC5D overlapped with H3K4me3 signal 
region(Figure s1)(34). 
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Identification of MDD-associated pathways in PGC:MDD 
Pathway analysis: using MAGENTA, only 1 pathway from REACTOME (role of 
second messengers in NETRIN1 signaling. That is a subset of the ‘the NETRIN1 
signaling pathway’ (100% overlap)(35)) was identified as associated with MDD after 
FDR correction(NFDR=1035) (Table 1). 
 
Regional heritability analysis: following the PGC published study, data from 9 
cohorts were grouped into 3 subsets for the GREML analysis((27) and Table s1). The 
estimate of   
  for MDD varied from 0.26 (se=0.06) to 0.47 (se=0.05) across subsets 
(Table s4B). The pathway-level regional heritability from the role of second 
messengers in the NETRIN1 signaling pathway was nominally significant using LRT 
in subset1(Plrt =0.017, Plrt_FDR=0.07), while it was not significant in subset2, subset3 
and the combined set(Table 2). Permutation test across the circularly permuted 
SNP-sets with the same set size in subset1 confirmed the enrichment of 
SNP-heritability in this pathway(Pperm=0.01)(Supplement). The gene-level regional 
heritability analysis for this pathway obtained nominal significance in one gene (DCC, 
Plrt=0.02) in subset1, no genes in subset2, one gene (TRPC3) in subset3 and two 
genes(PLCG1 and PITPNA) in the combined dataset (Table s5B). Since in subset1 the 
pathway-level regional heritability was significant for the role of second messengers 
in the NETRIN1 signaling pathway and the gene-level regional heritability was 
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significant in the DCC gene, we further localized the regional heritability by applying 
RHM to DCC in subset1(Table s6B). The distribution of the regional heritability for 
the DCC gene in subset1 was similar to that obtained for in GS:SFHS(Figure 2).  
 
Replication of GS:SFHS results in PGC:MDD and PGC:MDD results in 
GS:SFHS 
Among the four pathways identified by pathway analysis in GS:SFHS, the NETRIN1 
signaling pathway was replicated in PGC:MDD(Ppath =0.010, Nbonf =4+1=5, 
Ppath_bonf=0.05) whereas the other three pathways failed to replicate(Table 3). For the 
regional heritability analysis, among the 2 significant pathways in GS:SFHS, the 
NETRIN1 signaling pathway was significant in LRT in PGC:MDD subset1 (Plrt 
=0.00258, Nbonf = 2*(1+3)+1=9, Plrt_bonf=0.02), but not significant in other subsets or 
in the combined set(Table 4). The MTORC1 mediated signaling pathway failed to 
replicate in all subsets and in the combined set(Table 4). The gene-level regional 
heritability of DCC was nominally significant in both GS:SFHS(Table s5A) and in 
subset1 in PGC:MDD(Table s5B). The significant block 6 of DCC that was detected 
in GS:SFHS was fully covered by the nominally significant blocks in subset1(Figure 
2). 
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The only pathway identified by pathway analysis in PGC:MDD, the role of second 
messengers in NETRIN1 signaling pathway, was nominally significant in pathway 
analysis in GS:SFHS(Ppath =0.018, Nbonf =5, Ppath_bonf=0.09)(Table 3). For the regional 
heritability analysis, this pathway was nominally significant in LRT in GS:SFHS(Plrt 
=0.017, Nbonf = 9, Plrt_bonf=0.156)(Table 4). 
 
Estimation the predictive accuracy of Polygenic Risk Scores (PRS) derived from 
SNPs in the NETRIN1 signaling pathway or the whole genome 
We applied polygenic risk profiling to measure the additive genetic effect from the 
NETRIN1 signaling pathway and compared it with that from the whole genome(see 
methods).  
 
Using logistic regression, for both pathway and whole-genome SNP sets, PRSs 
created without LD clumping explained a higher proportion of variance compared 
with PRSs created with LD clumping((Table s7, Figure 3). The PRS created from the 
whole genome SNPs explained a maximum MDD variance of 0.198%(GWAS 
Pcutoff=0.2, without LD clumping. Pt-test=0.006.). The PRS created from SNPs in the 
NETRIN1 signaling pathway explained a maximum variance of 0.216%(GWAS 
Pcutoff=0.2, without LD clumping. Pt-test =0.004.)(Table s7). Permutation test across 
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the circularly permuted SNP-sets with the same set size suggested that the variance 
explained by the NETRIN1 signaling pathway PRS (without LD clumping) in the 
logistic regression model was significantly higher than expected by chance(Table s8).  
 
Using LMM, we estimated the proportion of MDD variance explained by pair-wise 
MDD-PRS similarity between individuals. A ‘PRS-bin relationship’ 
variance-covariance matrix was constructed and jointly fitted with a SNP-based 
genomic relationship matrix(GRM) in LMM. For each PRS, multiple bin numbers 
were tested to assess the stability of the model across different bin settings. When the 
comparison was between the PRSs created without LD clumping, the PRS-bin 
relationship matrices created from the NETRIN1 signaling pathway outperformed 
those created from the whole-genome set, as they consistently explained a significant 
proportion of variance across multiple bin settings and P value thresholds(Figure 4), 
with a maximum MDD variance explained of 1.7%(se=0.02, Plrt=0.013, Pperm =0.012. 
PRS setting: bin=50, GWAS Pcutoff=0.5.)(Table s9). Nonetheless for PRSs created 
with LD clumping, most of the PRS-bin relationship matrices, both created from the 
whole genome SNPs or from the pathway SNPs, failed to obtain significance in LRT, 
with 3 exceptions at low-bin-setting(bin=10, 20, 50) for the whole-genome PRS-bin 
relationship matrix(Figure 4), the maximum MDD variance explained is 2.47% 
(se=0.028, Plrt=0.028, Pperm =0.021. PRS setting: bin=10, GWAS Pcutoff=0.2)(Table 
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s9). When jointly fitting PRS-bin relationship matrices from the pathway and whole 
genomes as well as a GRM in LMM, the variance explained by the NETRIN1 
pathway PRS(without LD clumping) remained stable and significant(Table s10).  
 
Finally, the estimation of the area under the ROC curve suggested that in general the 
AUCs of MDD PRSs were low, ranging from 0.498 to 0.532, with the NETRIN1 PRS 
obtaining the highest AUC(AUCNETRIN1_max=0.532, AUCwhole_max=0.527)(Table s11). 
 
Discussion 
Typically, disease-associated pathways have been assumed to have the following 
features: (1) the genetic variants in them are shown to be associated with disease in 
association tests; (2) the genetic variants in them explain a significant proportion of 
phenotypic variance; and (3) the genetic proxies such as polygenic risk scores derived 
from them have valuable predictive power for the disease. Here we applied a pipeline 
that integrates pathway analysis and regional heritability analyses to two independent 
samples. This enables the identification of candidate pathways for MDD that address 
the first two features. By comparing results from each stage of the pipeline, we 
identified the NETRIN1 signaling pathway which has multi-level associations with 
MDD that are observed across samples. Finally, the polygenic profiling method 
provided additional evidence that this pathway also satisfied the third feature. 
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In the pathway analysis, we identified four MDD-associated pathways in GS:SFHS 
but only one in PGC:MDD by using two methods, GRASS and MAGENTA, 
respectively, as different data types were available from each dataset for this 
analysis(Supplement).  There was no pathway that was associated with MDD in both 
GS:SFHS and PGC:MDD. However the only associated pathway detected by 
MAGENTA in PGC:MDD, the role of second messengers in the NETRIN1 signaling 
pathway, was a subset of the NETRIN1 signaling pathway(100% overlap) which was 
detected by GRASS in GS:SFHS. Previous studies have suggested that the NETRIN1 
signaling pathway plays a crucial role in axon guidance, a process that establishes 
precise brain circuits during the development of the central nervous system(36). 
Interestingly, in the development stage of the thalamus, the response of embryonic 
thalamocortical axons to the NETRIN1 signaling is modulated by serotonin(5-HT) 
signaling, a system that has been repeatedly implicated in the etiology of 
MDD(37,38). Given these convergent lines of research, NETRIN1 signaling is a 
promising candidate pathway for MDD. 
 
The pathway analysis was followed by a pathway-level regional heritability analysis. 
We found that in both samples some of the MDD-associated pathways including the 
two NETRIN1 signaling pathways contributed significantly to explain MDD variance. 
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Moreover, the pathway-level regional heritability estimated was greater than that was 
expected given the SNP-set size in these pathways(Table 2), suggesting an 
enrichment of heritability further supported by the permutation test. These results 
were consistent with previous studies reporting enrichment of heritability in 
functionally annotated regions(12,13). 
 
In the NETRIN1 signaling pathway, key proteins affect axon guidance: DCC is the 
key receptor for the attractive response to Netrin-1, whereas UNC5, alone or together 
with DCC, is associated with the repulsive response to Netrin-1(36,39). In our study, 
the gene-based regional heritability analyses suggested that DCC and UNC5D were 
among the most associated genes in GS:SFHS, which is consistent with their 
functional importance in the NETRIN1 signaling pathway. In PGC:MDD, DCC was 
the only gene that attained nominal significance(in subset1, the only subset for which 
the pathway-level regional heritability from the candidate pathway is significant). 
When applying RHM to DCC, the regional heritability was localized to block6 in 
GS:SFHS (for PGC:MDD subset1 this region also obtains nominal 
significance)(Figure 2). Block6 overlapped with the fourth Immunoglobulin-like 
domain(Figure 2) which may be necessary for the axonal attraction mediated by 
Netrin-1 and draxin(40). A recent meta-analysis of GWAS for depressive symptom 
(N=180,886. The sample includes subjects from PGC MDD but the major source of 
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sample is from UK biobank(Nukb=105,739)) reported that one loci((rs62100776)) 
from the same gene DCC excessed genome-wide significance(41). This SNP is 
located in block7, which is adjacent to the significant block6 and is nominal 
significant in our study(Figure 2). This overlapped finding using a much larger 
sample size validated our results and indirectly supported the value of applying our 
pipeline in studies with small sample size. The significant block in UNC5D 
overlapped with a H3K4me3 modification, which implicates an active promoter in 
that region(42). These results imply a potentially functional contribution of variants in 
DCC and UNC5D to MDD.  
 
The pathway identified using our pipeline accounts for a significant proportion of 
phenotypic variance, which is an attractive feature for a biomarker. Polygenic risk 
scores(PRSs) were created by adding-up the genetic effects among biomarkers. 
Although MDD is a highly polygenic disorder, PRSs from whole genome SNPs can 
be noisy as they include SNPs with no effect on MDD. A more accurate prediction is 
likely from scores derived from biomarkers with a higher proportion of causal SNPs. 
We thus measured the prediction value for MDD of the PRSs derived from the 
associated NETRIN1 signaling pathway. The results showed that pathway-PRSs 
explain a higher proportion of phenotypic variance than whole-genome-PRSs, when 
PRS was fitted as a fixed effect in the logistic regression. The AUC statistics also 
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support a better prediction by the pathway-PRSs. We additionally developed a 
‘PRS-bin-relationship matrix’ method in which PRS-similarity was used to explain 
phenotypic variation of MDD in LMM. Using this method, the MDD phenotypic 
variance explained by the pathway-PRS and whole-genome-PRS was substantially 
increased to 1.70% and 2.47%, respectively. Although the largest variance explained 
by the pathway-PRS was smaller than the whole-genome-PRS, the pathway-PRS 
performed better in terms of the significance level in LRT across most of the tested 
bins(Figure 4).  
 
Notably, although the ‘PRS-bin relationship matrix’ is conceptually similar to the 
classic common-SNP-based GRM, a key difference was that the ‘PRS-bin 
relationship matrix’ took the information of the effect size of loci as estimated in the 
discovery sample, PGC:MDD, and the genotypes from the target sample, GS:SFHS, 
so that it measures the MDD-genetic-risk-similarity and the interpretation of the 
model which it fitted was across samples. This method also enabled the 
discrimination of genetic effects represented in the pathway-PRS, whole-genome-PRS 
and GRM when they were jointly fitted in LMM. Our results suggest that they 
explained distinct proportions of phenotypic variance(1.6% for pathway-PRS, 2.2% 
for whole-genome-PRS and 22.7% for whole-genome-GRM)(Table s10). 
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Limitations and further research: firstly, different methods were applied in different 
samples using different data formats in the pathway analysis. This may have 
influenced the consistency and the comparability of the results, and complicated their 
interpretation. Secondly, it is possible that the predictive accuracy of the NETRIN1 
signaling pathway measured in this study is inflated, as both samples were involved in 
the pipeline where this pathway was identified(albeit independently), further 
replication in independent populations would strengthen our findings. Note that 
although the multi-level regional-heritability analyses enable the fine-mapping of 
association signals, their P-values may be inflated as the fine-mapping was conducted 
at the same datasets where the pathways were identified. We therefore suggested a 
carefully interpretation of the LRT results from the regional heritability analyses, and 
we attach more importance to the comparisons of the regional heritability patterns 
across populations(Figure 2). Thirdly, the route by which NETRIN1 signaling 
pathway contributes to MDD is unknown. Future directions for increasing our 
understanding could include (1)exploring mutant DCC animal models of MDD, 
(2)testing of the interactions of NETRIN1-receptors with known MDD-associated 
proteins.  
 
In summary, this study shows that the NETRIN1 signaling pathway was associated 
with MDD in two independent samples. Variants in this pathway accounted for a 
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significant proportion of variance in susceptibility for MDD, and have valuable 
prediction power. These findings further support a role for NETRIN1 in the etiology 
of MDD and provide a basis for future studies.  
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Legends 
Table 1 Top 10 pathways in pathway analysis for MDD using GRASS on GS:SFHS 
and using MAGENTA on PGC:MDD. NFDR =1035. For GRASS results on GS:SFHS, 
four pathways yielded significance after FDR correction. For MAGENTA results on 
PGC:MDD, one pathway yielded significance after FDR correction. EXP # GENES 
ABOVE 95% CUTOFF: expected number of genes with a corrected gene P value 
above the 95 percentile enrichment cutoff. OBS # GENES ABOVE 95% CUTOFF: 
observed number of genes with a corrected gene P value above the 95percentile 
enrichment cutoff.  
Table 2 Pathway-level regional heritability analysis results for the significant 
pathways identified in pathway analysis for GS:SFHS and PGC:MDD.   
 : 
pathway-level regional heritability attributable to the pathway SNPs.   
   heritability 
attributable to the complement SNP set. LRT(h
2
R) P value and LRT(h
2
R) PFDR: 
Nominal P value and FDR adjusted P value from LRT for   
 .  Npathway_snp: SNP 
number in the pathway.  %     
 /%snp: the ratio of the percentage of      
 
 in 
pathway to the percentage of SNPs in the pathway. * - significant results after 
multiple test correction (5%).  
 
Table 3. Replication results of pathway analysis. Four pathways were identified from 
GS:SFHS in PGC:MDD and one pathway was identified from PGC:MDD in 
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GS:SFHS. Pbonf : adjusted P value using Bonferroni multiple testing correction. Nbonf 
=5. 
 
Table 4. Replication results of pathway-level regional heritability analysis. Two 
pathways were significant in GS:SFHS in PGC:MDD, and one pathway was 
significant in PGC:MDD in GS:SFHS.  LRT(h
2
R) P value: adjusted P value using 
Bonferroni multiple testing correction. Nbonf=9. 
 
Figure 1. The analytical pipeline, its application in identifying associated pathways 
with MDD and its findings in two independent samples: GS:SFHS and PGC:MDD. A: 
Design of the analytical pipeline. In the pipeline, pathway analysis was performed for 
1035 pathways, significant pathways were analysed using multi-level regional 
heritability analyses(RHA) in the framework of Genomic Restricted Maximum 
Likelihood analysis(GREML) to quantify and localize the genetic effects on MDD. In 
pathway analysis, GRASS was applied to the phenotype and genotype data of 
6,455individuals from the GS:SFHS sample. MAGENTA was applied to the summary 
data from PGC MDD GWAS on 18,659 individuals. B: The findings by the analytical 
pipeline in the two samples. The NETRIN1 signaling pathway was identified as 
associated pathway with MDD and the association signal were localized to its gene 
DCC and the sub-region level.   
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Figure 2 Genic region in DCC showing blocks used in REACTA on GS:SFHS and 
subset1 in PGC:MDD subset1(subsets 2 and 3 failed to obtained significance in the 
pathway-level regional heritability of NETRIN1 signaling pathway). In GS:SFHS, the 
sliding window (window size=200 SNPs) defined 9 blocks with average block size of 
179kb. In PGC:MDD subset1, window size=100 SNPs was used as the density of 
SNPs in PGC:MDD dataset was around half of that in GS:SFHS. This divided DCC 
into 8 blocks with average block size of 191kbs. Blue bar: insignificant region in LRT. 
Orange bar: significant region in LRT. Red bar: significant region in LRT after 
Bonferroni correction. Red dotted line: significant Block 6 in GS:SFHS, which 
overlaps with the fourth Ig (Immunoglobulin-like) domain. This region was fully 
covered by the nominal significant regions in subset1 in PGC:MDD.  
 
Figure 3. The phenotypic variance explained by polygenic risk score as a fixed effect 
in logistic regression. Perm Aver NETRIN1 NETRIN1 without LD clumping: the 
average Nagelkerke's R
2 
of 1000 PRSs created from permuted pathway SNPs (the 
circular permuted SNP-sets with the same set size).  
 
Figure 4. The LRT result from LMM showing the significance level of the 
phenotypic variance explained by PRS-bin relationship matrices derived from variants 
in whole genome and the NETRIN1 signaling pathway with or without LD clumping 
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at GWAS P value thresholds of 0.2, 0.5, and 1 using different bins. The color of the 
bars was designated by the bin number. Red line marks the significance level 
(Plrt=0.05). 
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Table 1. 
Ra
nk 
Datab
ase 
Pathway P 
value 
PFDR Eff Gene 
Size 
Exp # Genes Above 
95% Cutoff 
Obs # Genes Above  
95%  Cutoff 
GS:SFHS 
1 BioCa
rta 
Feeder 
pathway 
2.93E
-05 
2.14E-
02 * 
- - - 
2 Reacto
me 
ABCA 
transport
ers in 
lipid 
homeost
asis 
5.20E
-05 
2.14E-
02 * 
- - - 
3 Reacto
me 
NETRIN
1 
signaling 
6.20E
-05 
2.14E-
02 * 
- - - 
4 Reacto
me 
MTORC
1 
mediated 
signallin
g 
8.87E
-05 
2.30E-
02 * 
- - - 
5 BioCa
rta 
P35 
Alzheim
er’s 
pathway 
2.69E
-04 
5.58E-
02 
- - - 
6 BioCa
rta 
SODD 
pathway 
5.23E
-04 
8.59E-
02 
- - - 
7 Reacto
me 
Energy 
depende
nt 
regulatio
n of 
MTOR 
by LKB1 
AMPK 
7.46E
-04 
8.59E-
02 
- - - 
8 Reacto
me 
NFKB 
activatio
n 
through 
FADD 
RIP1 
7.47E
-04 
8.59E-
02 
- - - 
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pathway 
mediated 
by 
caspase 
8 and 10 
9 KEGG Taste 
transduct
ion 
6.48E
-04 
8.59E-
02 
- - - 
1
0 
Reacto
me 
ABC 
family 
proteins 
mediated 
transport 
8.68E
-04 
8.98E-
02 
- - - 
PGC:MDD 
1 Reacto
me 
Role of 
second 
messeng
ers in 
NETRIN
1 
signaling 
1.00E
-04 
1.46E-
02* 
8 0 4 
2 Reacto
me 
Defensin
s 
9.00E
-04 
2.04E-
01 
25 1 6 
3 Reacto
me 
NRAGE 
signals 
death 
through 
JNK 
1.50E
-03 
2.07E-
01 
36 2 7 
4 Reacto
me 
Beta 
defensin
s 
3.50E
-03 
2.75E-
01 
21 1 5 
5 Reacto
me 
Purine 
catabolis
m 
1.26E
-02 
3.11E-
01 
10 1 3 
6 Reacto
me 
Formatio
n of 
tubulin 
folding 
intermed
iates by 
CCT 
TRIC 
1.71E
-02 
6.67E-
01 
22 1 4 
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7 BioCa
rta 
AKAP13 
pathway 
1.88E
-02 
7.31E-
01 
12 1 3 
8 Reacto
me 
Chondro
itin 
sulfate 
dermatan 
sulfate 
metaboli
sm 
5.54E
-02 
7.41E-
01 
49 2 5 
9 Reacto
me 
Elevatio
n of 
cytosolic 
CA2 
levels 
5.67E
-02 
7.43E-
01 
10 0 2 
1
0 
Reacto
me 
Opsins 4.30E
-02 
7.46E-
01 
10 0 2 
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Table 2 
Pathway 
or Group 
h
2
R se(h
2
R) 
h
2
C se(h
2
C) 
LRT(
h
2
R)  
P 
value 
LRT(
h
2
R)  
PFDR 
Npathway 
SNPs 
%s
np 
%h
2
gwas 
%h
2
gwas/
%snp 
 
GS:SFHS 
Reacto
me 
MTO
RC1 
Media
ted 
Signal
ling 
0.00
6 
0.00
4 
0.24
0 
0.09
9 
7.70E
-03 
1.86E-
02* 
947  0.0
4  
2.40 54.84  
Reacto
me 
NETR
IN1 
Signal
ing 
0.01
4 
0.00
9 
0.22
4 
0.09
9 
9.28E
-03 
1.86E-
02* 
8809  0.4
1  
5.80 14.20  
BioCa
rta 
Feeder 
Pathw
ay 
0.00
4 
0.00
4 
0.25
1 
0.09
9 
3.77E
-02 
5.03E-
02 
507  0.0
2  
1.00 42.68  
Reacto
me 
ABCA 
Transp
orters 
In 
Lipid 
Home
ostasis 
0.00
0 
0.00
4 
0.25
1 
0.09
9 
5.00E
-01 
5.00E-
01 
1020  0.0
5  
0.00 0.00  
 
PGC:MDD: Role Of Second Messengers In NETRIN1 Signaling 
PGC:
MDD 
combi
ned 
0.00
01 
0.00
06 
0.26
16 
0.02
16 
3.77E
-01 
4.17E-
01 
1083 0.0
01 
0.00
05 
0.52 
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PGC:
MDD 
subset
1 
0.00
55 
0.00
34 
0.26
25 
0.05
96 
9.06E
-03 
3.62E-
02* 
1083 0.0
01 
0.01
93 
19.12 
PGC:
MDD 
subset
2 
0.00
10 
0.00
18 
0.46
55 
0.05
25 
2.56E
-01 
4.17E-
01 
1083 0.0
01 
0.00
34 
3.37 
PGC:
MDD 
subset
3 
0.00
04 
0.00
22 
0.44
42 
0.07
80 
4.17E
-01 
4.17E-
01 
1083 0.0
01 
0.00
14 
1.41 
 
Table 3 
Datab
ase 
Pathwa
y 
P 
value 
Pbonf Eff GENE 
SIZE 
EXP # GENES ABOVE 
95% CUTOFF 
OBS # GENES ABOVE 
95% CUTOFF 
GS:SFHS in PGC:MDD 
React
ome 
ABCA 
transpor
ters in 
lipid 
homeos
tasis 
5.39E
-01 
1.00E+
00 
15 1 1 
React
ome 
NETRI
N1 
signalin
g 
9.90E
-03 
4.95E-
02 * 
37 2 6 
React
ome 
MTOR
C1 
mediate
d 
signalli
ng 
4.05E
-01 
1.00E+
00 
10 1 1 
BioCa Feeder 
pathwa
1.00E 1.00E+ 9 0 0 
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rta y +00 00 
PGC:MDD in GS:SFHS 
React
ome 
Role of 
second 
messen
gers in 
NETRI
N1 
signalin
g 
1.75E
-02 
8.76E-
02 
- - - 
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Table 4. 
GS:SFHS in 
PGC:MDD: 
Group 
NETRIN1 Signaling 
 
MTORC1 Mediated Signalling 
h2R Se 
(h2R
) 
h2C Se 
(h2C) 
LRT(
h2R) P 
value 
LRT(h
2
R) Pbonf 
h2R se(h
2
R) 
h2C se(h
2
C) 
LRT(
h2R) P 
value 
LRT(h2R) 
Pbonf 
Combined 0.00
0 
0.00
1 
0.26
2 
0.02
2 
4.75E-
01 
1.00E+
00 
0.000
3 
0.00
05 
0.28
43 
0.02
20 
2.71E-
01 
1.00E+00 
Subset1 0.01
4 
0.00
6 
0.25
6 
0.05
9 
2.59E-
03 
2.33E-0
2* 
0.000
6 
0.00
15 
0.26
47 
0.05
97 
3.32E-
01 
1.00E+00 
Subset2 0.00
3 
0.00
4 
0.46
3 
0.05
2 
1.59E-
01 
1.00E+
00 
0.001
8 
0.00
19 
0.46
43 
0.05
24 
1.02E-
01 
9.17E-01 
Subset3 0.00
2 
0.00
5 
0.44
3 
0.07
8 
3.83E-
01 
1.00E+
00 
0.000
0 
0.00
18 
0.44
47 
0.07
81 
5.00E-
01 
1.00E+00 
PGC:MDD in GS:SFHS: Pathway h2R se(h
2
R) 
h2C se(h
2
C) 
LRT(
h2R) P 
value 
LRT(h2R) 
Pbonf 
Reactome Role Of Second Messengers In NETRIN1 Signaling 0.005 0.00
4 
0.23
5 
0.09
9 
1.73E-
02 
1.56E-01 
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